Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

AlphaFold

AI overview

Sign in and the AI will write an overview from our coverage.

Headlines · 14

  1. As AI Spreads, Corporate Advantage Shifts to Leadership Judgment

    TMTPost argues that AI is taking over increasingly standardized work such as retrieval, calculation, drafting and checking, making access to computing and information less differentiating. It compares Nvidia, Apple and Microsoft, then draws on management theory to argue that leaders’ problem framing, resource allocation, conflict handling and long-term objectives may matter more as technology becomes widely available. The analysis presents possible mechanisms, not proof that a particular leadership style determines business or wealth outcomes.

    钛媒体 · 🔥 0
  2. Anthropic’s biomedicine strategy targets closed-loop drug discovery

    A 36Kr review examines Anthropic’s biomedicine push, including Claude Science, the Model Hardware Standard for laboratory equipment, protein-design agents, wet-lab partnerships, and the Mithril and Coefficient Bio acquisitions. The review says Anthropic is using Claude to orchestrate molecular-design models such as BoltzGen and is building a “pipeline-in-a-person,” while wet-lab validation remains a constraint. It characterizes biomedicine as Anthropic’s next concentrated investment focus after coding and says the strategy is more focused than OpenAI’s broader life-science activities, though that comparison is editorial judgment.

    36氪 人工智能 · 🔥 0
  3. Can AI Trained on Historical Data Rediscover Relativity?

    A Nature feature by Philip Ball examines experiments using historical-data language models to test whether AI can recreate scientific breakthroughs. At the India AI Summit, Google DeepMind co-founder Demis Hassabis proposed training a model on knowledge available through 1911 and asking whether it could independently rediscover general relativity, calling this a useful test of AGI. Preliminary experiments produced mixed results. Michael Hla's Machina Mirabilis model showed occasional flashes of intuition, such as describing light as discrete pulses, but often failed to understand the physics it invoked. Other researchers reported difficulty separating correct from incorrect theories, judging which ideas were worth testing and preventing information from beyond the historical cutoff from entering the training data.

    虎嗅 AI · 🔥 0
  4. Researchers Argue Current AI Lacks Consciousness

    In a Nature commentary, Anil Seth, Ned Block, and Giulio Tononi argue that current AI systems lack subjective experience and are unlikely to become conscious through silicon-based architectures. Drawing on intelligence research, computational functionalism, and Integrated Information Theory, they reject the assumption that performing the right computations is sufficient for consciousness. Their conclusion is firmer than the Butlin report, which found current systems unlikely consciousness candidates but left the possibility of future systems open.

    The Decoder · 🔥 0
  5. PDB marks 55 years and expands AI-predicted structures

    TechNews reports that the Protein Data Bank marked its 55th anniversary, growing from seven X-ray crystal structures in 1971 to more than 260,000 atomic-level 3D models. The report also says RCSB.org now offers over one million computer-predicted structure models that can be browsed and analyzed with the same tools used for PDB.

    科技新报 · 🔥 0
  6. Amodei’s AI disease-cure forecast draws medical scrutiny

    Anthropic CEO Dario Amodei said in an IPO roadshow video that properly applied AI could make cancer, Alzheimer’s disease, heart disease and mental illness history in under a decade. Medical and pharmaceutical experts cited by IT之家 and 36氪 questioned the timeline, noting that laboratory testing, animal studies, clinical trials and regulatory approval remain necessary; as of 2026, no AI-designed drug had reached broad clinical use.

    虎嗅 AI · 🔥 0
  7. Isomorphic Labs President Predicts AI Will Design All Drugs

    Isomorphic Labs President Max Jaderberg said he expects AI eventually to design all drugs, while acknowledging that the timing is uncertain. The company remains in preclinical development and plans to begin its first clinical trial by the end of 2026 to test AI-designed candidates in patients. Its IsoDDE drug-design engine is supported by company-published technical results that have not yet been independently validated.

    MIT科技评论中文 · 🔥 0
  8. Pinal Brings Natural-Language Prompts to Protein Design

    Researchers in China developed Pinal, an AI-assisted tool that accepts natural-language descriptions of protein functions and generates candidate protein sequences, according to Ars Technica. Tests produced some functional designs, but the yield was low: among 29 fluorescent-protein candidates tested in E. coli, only one fluoresced. Pinal therefore reduces the need for detailed structural specifications but still requires specialist screening and laboratory validation.

    Ars Technica AI · 🔥 0
  9. AI drug discovery pivots toward digital twins and virtual cells

    A Huxiu AI reprint of a Shenlan Guan article reports that this autumn the AI drug discovery field's attention is shifting from molecule generation toward digital twins and virtual cells, with practitioners saying the direction has been repeatedly raised since summer and that many AIDD companies now describe plans to move into virtual cells. The report says that in early October Mark Zuckerberg's Biohub expanded its virtual biology program to $1.8 billion, working with the US Department of Energy, NIH and Google DeepMind to build public data infrastructure for virtual cell models, and that nearly 10 related funding deals have appeared in China since April 2026. It also lists bottlenecks: calibrated dynamic time-series quantitative single-cell data is scarce, single-cell sequencing yields only snapshots, and models struggle to pass wet-lab validation of extrapolation and drug-perturbation prediction; virtual clinical trials and digital-twin diagnostics also lack mature regulatory and review standards, and the business model remains unclear.

    虎嗅 AI · 🔥 0
  10. DeepMind and Biohub on why AlphaFold hasn't solved protein folding

    In a Latent Space panel, Google DeepMind's Pushmeet Kohli and Biohub's Sal Candido said AlphaFold's breakthrough was only a beginning: static structure prediction does not cover protein dynamics, disorder, or whole biological systems. They argued that biology cannot simply import the "bitter lesson" of scaling, and that researchers should define the problem first, then decide whether to invest in modeling, compute or data generation. As one example, they said training protein language models on lower-quality metagenomic sequences can still improve design of real, working proteins, while building a virtual cell still lacks the right data.

    Latent Space · 🔥 0
  11. Google DeepMind Institute essay: AI as an 'invention of a method of invention'

    Google DeepMind Institute published an essay, "Bending the Curve of Discovery," by Alex Imas and James Manyika on AI and science. It argues that today's LLMs and specialized models like AlphaFold act as economic complements, with most handoffs between them still run by the scientist; in a possible future, LLMs would orchestrate those handoffs automatically — prompting specialized models, auditing outputs and looping until a question is answered or a non-automated stage such as wet-lab testing is reached — shifting the scientist's role to designing that loop. The authors also raise epistemic questions about scientific understanding, theory-building, training the next generation of scientists and motivation, and note that as hypothesis generation gets cheap the bottleneck moves downstream to verification and choosing which questions matter, making this an organizational and institutional challenge as much as a technical one.

    Google DeepMind (X) · 🔥 0
  12. Isomorphic Labs in talks to raise at $40B–$50B valuation

    Isomorphic Labs, the AI drug discovery company spun out of Alphabet's Google DeepMind, is in early talks to raise new funding at a valuation of at least $40 billion, according to Bloomberg. SiliconANGLE, citing the same report, says the valuation range could reach $50 billion, though the size of the round was not disclosed. The company's flagship IsoDDE platform targets drug design tasks such as binding pocket discovery; Isomorphic has claimed it outperforms AlphaFold on some of these tasks, figures that come from the company itself.

    Bloomberg Technology · 🔥 0
  13. Rivercell raises $25M to build an AI virtual cell model

    Rivercell has raised a $25M seed round led by HV, with HCVC, Alven and Bpifrance Digital Venture participating. The money will fund its data platform, a larger wet lab in Paris and its AI Virtual Cell programme, which the company describes as a world model of the cell that predicts how a cell changes after treatment. Rivercell says no dataset of comparable scale exists for how cells respond to drugs over time, so it plans to generate its own by filming living cells through each experiment and reading their gene activity, with the model choosing the next experiment and the company building its own instruments.

    The Next Web · 🔥 0
  14. Eric Betzig Warns AlphaFold Alone Cannot Solve Drug Discovery

    Nobel laureate Eric Betzig argued in a podcast interview that using AlphaFold protein structures alone for drug discovery is unlikely to succeed, because cells are dynamic, crowded, multiscale systems. He proposed combining live-cell 4D/5D imaging, self-supervised vision Transformers and zebrafish models to study drug effects from molecules to whole organs, while also criticizing academic incentives built around papers, grants and peer review.

    MIT科技评论中文 · 🔥 0

Experience and discussion from the community

Share my AlphaFold experienceAsk about AlphaFold

Nobody has shared their experience with AlphaFold yet.